HomeCompareRAD vs ORCC

RAD vs ORCC: Dividend Comparison 2026

RAD yields 308.50% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAD wins by $1828.42M in total portfolio value
10 years
RAD
RAD
● Live price
308.50%
Share price
$0.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1828.44M
Annual income
$1,116,502,790.12
Full RAD calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — RAD vs ORCC

📍 RAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRADORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAD + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAD pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAD
Annual income on $10K today (after 15% tax)
$26,222.43/yr
After 10yr DRIP, annual income (after tax)
$949,027,371.60/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, RAD beats the other by $949,027,370.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAD + ORCC for your $10,000?

RAD: 50%ORCC: 50%
100% ORCC50/50100% RAD
Portfolio after 10yr
$914.23M
Annual income
$558,251,395.58/yr
Blended yield
61.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

RAD
Analyst Ratings
3
Buy
4
Hold
3
Sell
Consensus: Hold
Price Target
$7.00
+979.7% upside vs current
Range: $7.00 — $7.00
Altman Z
0.7
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAD buys
0
ORCC buys
0
No recent congressional trades found for RAD or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRADORCC
Forward yield308.50%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1828.44M$21.4K
Annual income after 10y$1,116,502,790.12$1.04
Total dividends collected$1757.69M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$7.00$16.00

Year-by-year: RAD vs ORCC ($10,000, DRIP)

YearRAD PortfolioRAD Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$41,550$30,849.92$11,190$489.61+$30.4KRAD
2$164,254$119,795.45$12,229$256.01+$152.0KRAD
3$618,342$442,590.42$13,216$130.74+$605.1KRAD
4$2,218,780$1,557,153.50$14,207$66.02+$2.20MRAD
5$7,596,048$5,221,953.60$15,234$33.17+$7.58MRAD
6$24,835,706$16,707,934.61$16,317$16.62+$24.82MRAD
7$77,627,974$51,053,769.25$17,468$8.32+$77.61MRAD
8$232,199,063$149,137,130.73$18,695$4.16+$232.18MRAD
9$665,364,825$416,911,827.36$20,006$2.08+$665.34MRAD
10$1,828,443,153$1,116,502,790.12$21,407$1.04+$1828.42MRAD

RAD vs ORCC: Complete Analysis 2026

RADStock

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and provides various other pharmacy services and an assortment of products comprising over-the-counter medications, health and beauty aids, personal care products, seasonal merchandise, cosmetics, household items, food and beverages, greeting cards, seasonal and general merchandise, pet care, and a variety of other everyday and convenience products, as well as brand and generic prescription drugs; and a private brand product line. It also operates retail pharmacies and clinics; and offers healthcare services, including administering immunizations for COVID-19, the flu, shingles, and others; assists its customers with high blood pressure, cholesterol, and diabetes; provides guidance on combating obesity and tobacco addiction; and educates customers on managing medications and potential side effects. In addition, this segment offers healthcare coaching and disease management services to health plans and employers. The Pharmacy Services segment provides integrated suite of pharmacy benefit management (PBM) offerings, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs, as well as drug benefits under the federal government's Medicare Part D program and insurance offerings for individuals and groups. This segment serves health plans, commercial employers, labor groups, and state and local governments. As of February 26, 2022, the company operated 2,450 retail pharmacy locations in 17 states. Rite Aid Corporation was founded in 1962 and is headquartered in Philadelphia, Pennsylvania.

Full RAD Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this RAD vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAD vs SCHDRAD vs JEPIRAD vs ORAD vs KORAD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.